ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
By H. Schmoll, E. Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C. Velde, J. Balmaña, J. Reguła and 27 more. Annals of Oncology, 2012
1,471 citations recorded by the source corpus.
Subfields: Oncology
View Paper: https://www.semanticscholar.org/paper/7fe32bf7fe5b219ddfd130d03e83fe019ba26b16
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “are considered at high risk of colon cancer and must be actively screened and, in cases of inherited syndromes, also referred for genetic counselling [7, 9].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Historically, ‘fit’ patients with mCRC were categorised according to the previous ESMO consensus guidelines into four groups (0, 1, 2, and 3) to determine the strategic treatment approaches (Table 5) [3, 5].”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “In patients with metastatic rectal cancer with symptoms of the primary tumour, irradiation (possibly combined with chemotherapy) of the primary tumour should be considered after discussion with the radiation oncologist in order to obtain optimal symptom control of the primary tumour [51].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, background): “• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”